ZA9811823B - Use of chelating agents in the treatment of atherosclerotic conditions. - Google Patents

Use of chelating agents in the treatment of atherosclerotic conditions.

Info

Publication number
ZA9811823B
ZA9811823B ZA9811823A ZA9811823A ZA9811823B ZA 9811823 B ZA9811823 B ZA 9811823B ZA 9811823 A ZA9811823 A ZA 9811823A ZA 9811823 A ZA9811823 A ZA 9811823A ZA 9811823 B ZA9811823 B ZA 9811823B
Authority
ZA
South Africa
Prior art keywords
group
alkyl
optionally
hydrogen atom
hydrogen
Prior art date
Application number
ZA9811823A
Other languages
English (en)
Inventor
Jan Olof Gustav Karlsson
Rolf Goran Gustav Andersson
Anders Olsson
Bo Zieden
Per Jynge
Tudor Griffith
Derek Grant
Robertson Towart
Helge Refsum
Original Assignee
Nycomed Imaging As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nycomed Imaging As filed Critical Nycomed Imaging As
Publication of ZA9811823B publication Critical patent/ZA9811823B/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Treatment Of Water By Ion Exchange (AREA)
  • Semiconductor Lasers (AREA)
ZA9811823A 1997-12-23 1998-12-23 Use of chelating agents in the treatment of atherosclerotic conditions. ZA9811823B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9727224.9A GB9727224D0 (en) 1997-12-23 1997-12-23 Method

Publications (1)

Publication Number Publication Date
ZA9811823B true ZA9811823B (en) 1999-08-24

Family

ID=10824152

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9811823A ZA9811823B (en) 1997-12-23 1998-12-23 Use of chelating agents in the treatment of atherosclerotic conditions.

Country Status (9)

Country Link
US (1) US6310051B1 (xx)
EP (1) EP1054670B1 (xx)
JP (1) JP4831383B2 (xx)
AT (1) ATE290379T1 (xx)
AU (1) AU1770199A (xx)
DE (1) DE69829315T2 (xx)
GB (1) GB9727224D0 (xx)
WO (1) WO1999033521A2 (xx)
ZA (1) ZA9811823B (xx)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2823977B1 (fr) 2001-04-26 2006-12-01 Univ Rene Descartes Utilisation du mangafodipir dans le traitement des effets d'un stress oxydatif
DE10135494A1 (de) * 2001-07-20 2003-11-06 Jobst Krauskopf Verwendung eines Lactatsalzes zur Behandlung und Prophylaxe der Athereosklerose
RU2491282C2 (ru) 2007-12-14 2013-08-27 Пледфарма Аб Соединения, предназначенные для лечения рака
BR112012000262A2 (pt) * 2009-07-06 2016-02-16 Pledpharma Ab composição farmacêutica, e, método de tratamento de uma condição.
WO2013102806A1 (en) 2012-01-05 2013-07-11 Pledpharma Ab Calmangafodipir, a new chemical entity, and other mixed metal complexes, methods of preparation, compositions, and methods of treatment
MX2015005519A (es) 2012-11-02 2015-07-17 Pledpharma Ab Metodos de tratamiento de cancer.
WO2018075641A1 (en) * 2016-10-19 2018-04-26 Longevica Therapeutics Inc. Methods and compositions for extending lifespan
CN110139673B (zh) 2016-11-14 2022-03-22 卡尔森图纳投资公司 使用非过渡金属配位的二吡哆基化合物以预防和治疗化疗诱发的psn

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3838196A (en) * 1972-09-25 1974-09-24 J Mercer Method of treating arteriosclerosis
EP0214101A3 (de) * 1985-09-03 1989-05-31 Ciba-Geigy Ag Verwendung von Eisen(III)-Chelatoren vom Typ Desferrioxamin B und Desferriferrithiocin zur Behandlung von Malaria
US4935518A (en) * 1987-05-08 1990-06-19 Salutar, Inc. Manganese(II), chelate contrast agents derived from N,N'-bis-(pyridoxal ethylene diamine-N,N')-diacetic acid and derivatives thereof
US4842845A (en) * 1987-05-08 1989-06-27 Salutar, Inc. Radioactive metal chelates for dipyridoxyl phosphate
EP0466200B1 (en) * 1987-07-16 1996-04-24 Nycomed Imaging As Aminocarboxylic acids and derivatives thereof
EP0368223A3 (de) * 1988-11-10 1991-09-25 Hoechst Aktiengesellschaft Verwendung von Ethylendiamintetraessigsäure als Inhibitor der Calcium/Calmodulin abhängigen Proteinkinase II oder der Proteinkinase C
FR2645442A1 (fr) * 1989-04-07 1990-10-12 Gueyne Jean Produit therapeutique a base de compose organique du silicium et de polyamine polycarboxylee, particulierement utile pour le traitement de l'atherome
GB9211779D0 (en) * 1992-06-03 1992-07-15 Ciba Geigy Ag Amine salts
GB9613182D0 (en) * 1996-06-24 1996-08-28 Nycomed Imaging As Method

Also Published As

Publication number Publication date
AU1770199A (en) 1999-07-19
WO1999033521A2 (en) 1999-07-08
EP1054670B1 (en) 2005-03-09
JP4831383B2 (ja) 2011-12-07
GB9727224D0 (en) 1998-02-25
WO1999033521A3 (en) 1999-09-02
DE69829315D1 (de) 2005-04-14
JP2001527053A (ja) 2001-12-25
ATE290379T1 (de) 2005-03-15
DE69829315T2 (de) 2006-04-13
EP1054670A2 (en) 2000-11-29
US6310051B1 (en) 2001-10-30

Similar Documents

Publication Publication Date Title
NZ333315A (en) Dipyridoxyl chelating agents and their metal chelates for treating free radicals induced conditions
ATE241601T1 (de) Zwischenverbindungen zur herstellung von neunen pyridoncarbonsäurederivate oder deren salzen
DK0787726T3 (da) Ny forbindelse, fremgangsmåde til fremstilling deraf og antitumor-middel
HUT77925A (hu) Dihidrobenzofuránok, azokat tartalmazó gyógyászati készítmények és eljárás előállításukra
ATE186727T1 (de) Substituierte 3-arylidinene-7-azaoxindol verbindungen und verfahren zu ihrer herstellung
GB8726714D0 (en) Compounds
ATE120191T1 (de) Makrocyclische chelatisierungsmittel und daraus hergestellte chelate.
AR004672A1 (es) Derivados de la banzo(g)quinolina, proceso para prepararlos,su utilizacion como productos farmaceuticos, las composiciones farmaceuticas que los contieneny los metodos de tratamiento de la depresion, ansiedad y desordenes bipolares que utilizan dichos compuestos.
PT76450A (de) Spiro/4.(3+n)-2-aza-3-carbonsaeure-derivate verfahren zu ihrer herstellung diese enthaltende mittel und ihre verwendung
ZA9811823B (en) Use of chelating agents in the treatment of atherosclerotic conditions.
DE69814608D1 (de) Verfahren zur herstellung von 2-thienylamin-derivaten
DE69924119D1 (de) Verfahren zur herstellung von n-(phosphonomethyl)glycin durch oxidation von n-substituierten n-(phosphonomehtyl)glycin
DK0874812T3 (da) Hidtil ukendte 2,3,5-trimethyl-4-hydroxyanilidderivater, fremstilling deraf og terapeutisk anvendelse deraf
ATE468109T1 (de) Liposomale abgabe von verbindungen auf vitamin-e- basis
UY25143A1 (es) Procedimiento para la preparacion de inhibidores de proteasas.
DE60016039D1 (de) Verfahren und verbindungen für die hemmung von mrp1
DE69936250D1 (de) Mittel zur Entfernung von sauren Komponenten, Verfahren zu seiner Herstellung und Methode zur Entfernung von sauren Komponenten
ATE166342T1 (de) Desferrioxamine-b salze und ihre verwendung als oral wirksame eisen- chelatbildner
DE3777482D1 (de) Mittel zur therapie faktor viii-resistenter haemophilie a und verfahren zu seiner herstellung.
DE59507361D1 (de) Cyclohexan-Derivate, Verfahren zu ihrer Herstellung und die Verwendung als Glukose-6-Phosphatase Inhibitoren
AR246967A1 (es) Novedosos derivados de 3-perfluoroalquil-oxi-isoxazoles-5-substituidos y composiciones herbicidas que los contienen y procedimiento para prepararlos.
ATE262337T1 (de) Azasteroidverbindung zur behandlung von alopezie, hirsutismus und seborrhoe
FR2737207B1 (fr) Nouvelles n-heterocyclyl-1-aryloxyalcoyl-4-piperidinamines substituees, leur preparation et leur application en therapeutique
AR023332A1 (es) Compuestos derivados de benzamida sustituidos, proceso para su preparacion, formulaciones farmaceuticas que los comprenden, y metodo de tratamiento
ES8707939A1 (es) Procedimiento para preparar derivados de n-carboxialquil-2--oxo-3-diaril-5,6-triazinas